Mechanisms of Accelerated Liver Fibrosis in HIV-HCV Coinfection
Mechanisms of Accelerated Liver Fibrosis in HIV-HCV Coinfection
复制标题
DOI：
10.24875/aidsrev.m17000004
复制
发表时间：
2017-07-01
期刊：
影响因子：
2.2
通讯作者：
Germanidis, Georgios
中科院分区：
文献类型：
--
作者：
Chrysanthidis, Theofilos;Loli, Georgia;Germanidis, Georgios
虽然有证据表明，丙型肝炎病毒（HCV）在HIV/HCV合并感染患者中的进展速度比HCV单感染患者快，但HIV-、HCV-和宿主/遗传相关因素以及这一过程中涉及的确切机制尚未完全阐明。此外，新的抗病毒药物似乎可以治愈合并感染者的丙型肝炎病毒，但高昂的费用以及不充分的识别、与护理和治疗的联系阻碍了这一目标的实现。对个体的研究可以揭示一个重要的预后指标，用于说服HIV/HCV合并感染并预测纤维化进程加速的患者的有效性，不仅在指南方面，而且在现实生活中，以医学公正的框架促进和优先考虑他们的治疗。
Although there is evidence that hepatitis C virus (HCV) progresses rapidly in HIV/HCV-coinfected patients in comparison with HCV monoinfected, the HIV-, HCV-, and host-/genetic-related factors, as well as the exact mechanisms implicated in this process, are not fully elucidated. Furthermore, cure of HCV in those coinfected seems possible with the new antiviral drugs, but high cost as well as insufficient identification, linkage with care, and treatment hamper the achievement of this goal. Research on the individual could reveal an important prognostic marker for the effectiveness of persuasion of patients with HIV/HCV coinfection with a predicted accelerated fibrosis course, to facilitate and prioritize, not only in terms of guidelines but also in the real-life situation, their treatment with a medically just framework.